23311-38-8

Upstream product

• 14898-67-0 ruthenium trichloride hydrate 
• 603-35-0 triphenylphosphine 
• 7647-01-0 hydrogenchloride 
• 14898-67-0 ruthenium trichloride trihydrate 
• 63767-78-2 ruthenium trichloride 

Downstream Products

• 124464-32-0 Ru(SC₆F₄H)3(P(C₆H₅)3)2 
• 124444-46-8 Ru(SC₆FH₄)3(P(C₆H₅)3)2 
• 76941-25-8 RuCl₂(C₇H₄BrO₂)(P(C₆H₅)3)2 
• 303089-83-0 RuCl₂(PPh₃)2(2-O-3-OMe-C₆H₃CHNC₆H₄Me-2) 
• 303089-79-4 RuCl₂(PPh₃)2(2-O-3-OMe-C₆H₃CHNPh) 
• 303089-87-4 RuCl₂(PPh₃)2(2-O-3-OMe-C₆H₃CHNC₆H₄Me-3) 
• 303089-91-0 RuCl₂(PPh₃)2(2-O-3-OMe-C₆H₃CHNC₆H₄Me-4) 
• 367501-63-1 [2-SC₆H₄NCPh]2CH₂RuCl(PPh₃) 
• 440106-79-6 RuCl₂(anth-p-tol)(triphenylphosphine)2 
• 339556-75-1 [RuCl₂(PPh₃)2(sal-m-toluidine)] 

Relevant academic research and scientific papers

Monitoring the DNA by ruthenium complexes of heterocyclic N,S-donor ligands and evaluation of biological activities

Neutral N,S-donor bidentate ligands have been synthesized and characterized by NMR and IR spectroscopic techniques. The ligands have been used to synthesized ruthenium(II) complexes ([Ru(L1–L6)PPh3)2Cl2/su

Synthesis, X-ray structure, physicochemical properties and anticancer activity of: Mer and fac Ru(iii) triphenylphosphine complexes with a benzothiazole derivative as a co-ligand

Two mononuclear ruthenium(iii) mer- and fac-isomers of the formula [RuCl3(PPh3)(dmpbt)] (where PPh3 = triphenylphosphine, dmpbt = 2-(3,5-dimethylpyrazoll-yl)benzothiazole) have been synthesised from the reaction of [RuCl3(PPh3)3] with a bidentate ligand-dmpbt. Appropriate reaction conditions allowed obtaining the two isomers separately without separation techniques. X-ray crystallography has determined the crystal and molecular structures of the new complexes. mer-Ru(iii) (1) crystallised in the monoclinic P2(1)/n group, and fac-Ru(iii) (2, 2′) in the triclinic P1 space group. The composition of the ruthenium coordination sphere was confirmed and characterised using spectroscopic techniques (FT-IR, UV-vis and EPR), elemental analysis and mass spectrometry (MS-FAB). The structures of the complexes obtained were analysed using X-ray and other spectroscopic methods (IR and UV-vis). The electrochemical properties of the ligand and the complex compound were identified using cyclic voltammetry, determining the potential and charge of faradaic processes. Both isomers are redox active and display quasi-reversible metal centered redox processes for the Ru(iii)/Ru(ii) pair. Moreover, preliminary tests of their biological activity were performed. The cytotoxicity of these compounds has been tested for human lung carcinoma (A549), chronic myelogenous leukemia (K562), human cervix carcinoma (HeLa) cells, acute lymphoblastic leukemia (MOLT-4), human breast adenocarcinoma cell line (MCF-7) and normal human umbilical vein endothelial cells (HUVEC). The ability to induce apoptosis has been demonstrated in caspase 3/7 activity assay. In addition, the lipophilicity of both isomers was described by a partition coefficient, logP, values of which were estimated by the shake-flask method. The interesting and promising preliminary results of the biological and chemical activities of the new octahedral mer/fac Ru(iii) complexes motivate further in vitro and in vivo studies.

Synthesis, characterization and biological evaluation of Ru(III) mercaptopyrimidine Schiff base complexes

A new series of mercaptopyrimidine Ru(III) complexes were synthesized and characterized using various spectral techniques like single-crystal X-ray diffraction, Fourier transform infrared and NMR spectroscopies, thermogravimetric analysis and energy-dispersive X-ray analysis. The complexes were evaluated for their pharmacological activities like in vitro antimicrobial, anticancer, antituberculosis and antioxidant activities. The DNA binding of the complexes was investigated by absorption and emission spectral measurements which indicated that the complexes bind to DNA via intercalation, with molecular docking studies validating the results. DNA cleavage studies of the complexes were carried out.

DNA Interaction, in vitro Antibacterial and Cytotoxic Activities of Ru(III) Heterochelates

Ruthenium(III) complexes [Ru(bphtpy)(PPh3)Cl3] (bphfpy = diphenylfuranylpyridine derivatives) were synthesized and characterized by LCMS, IR spectroscopy, elemental analysis and magnetic measurements. All the complexes were screened

Synthesis and characterization of new complexes formed by insertion of carbon disulphide in RuL3Cl3 (L=PPh3 and AsPh3)

Reaction of RuL3Cl3 (L=PPh3 and AsPh 3) with stoichiometric amount of CS2 in ethanol-dichloromethane mixed solvent systems at room temperature yields paramagnetic complexes of the type [RuL2Cl2(S 2COEt)]-The complexes have been characterized by conductance, IR, electronic, ESR spectral, magnetic moment measurement and thermal data as well as by elemental analysis. The appearance of three g-values in the ESR spectra reveal a highly distorted octahedral environment around ruthenium(III) ion with one bidented EtOCS2 ligand.

Synthesis, spectral and electrochemical studies of ruthenium(II)/(III) complexes of alicyclic β-ketamines

A series of ruthenium(II)/(III) complexes of alicyclic β-ketamines derived from 2-formylcyclohexanone and 4-X-substituted anilines, HFCA-X (where H is an ionisable enolic hydrogen and X = H, Cl, Br, OMe and NO2), have been prepared and characterized by spectroscopic techniques. The IR spectral data suggest the coordination of enolic oxygen and imino nitrogen to ruthenium. Ruthenium(II) complexes are diamagnetic (low spin d6, S = 0) and in solutions show intense MLCT transition. Their redox behaviours have been studied by cyclic voltammetry. The solid state low temperature ESR spectra of Ru(III) complexes show a low spin symmetry.